Inspire Investing LLC Purchases 13,470 Shares of Embecta Corp. $EMBC

Inspire Investing LLC increased its position in Embecta Corp. (NASDAQ:EMBC) by 49.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,771 shares of the company’s stock after acquiring an additional 13,470 shares during the period. Inspire Investing LLC’s holdings in Embecta were worth $395,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EMBC. Banque Transatlantique SA grew its holdings in shares of Embecta by 879.1% in the first quarter. Banque Transatlantique SA now owns 3,701 shares of the company’s stock worth $44,000 after acquiring an additional 3,323 shares during the period. Brooklyn Investment Group grew its holdings in shares of Embecta by 1,164.1% in the first quarter. Brooklyn Investment Group now owns 3,590 shares of the company’s stock worth $46,000 after acquiring an additional 3,306 shares during the period. Wealthquest Corp bought a new stake in shares of Embecta in the first quarter worth $48,000. Picton Mahoney Asset Management bought a new stake in shares of Embecta in the first quarter worth $50,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Embecta by 1,261.1% in the first quarter. Exchange Traded Concepts LLC now owns 7,391 shares of the company’s stock worth $94,000 after acquiring an additional 6,848 shares during the period. Institutional investors own 93.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on EMBC shares. Zacks Research lowered Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and set a $25.00 target price on shares of Embecta in a research report on Friday, September 5th. Mizuho lowered their target price on Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 16th. Finally, Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Embecta presently has an average rating of “Hold” and a consensus target price of $19.00.

Embecta Stock Down 0.2%

NASDAQ EMBC opened at $13.35 on Tuesday. The firm has a market cap of $780.84 million, a price-to-earnings ratio of 9.34, a price-to-earnings-growth ratio of 0.74 and a beta of 1.10. The business has a 50-day moving average price of $13.98 and a 200-day moving average price of $12.07. Embecta Corp. has a twelve month low of $9.20 and a twelve month high of $21.48.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.35. The firm had revenue of $295.50 million during the quarter, compared to analyst estimates of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.74 earnings per share. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Research analysts expect that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 29th were paid a $0.15 dividend. The ex-dividend date of this dividend was Friday, August 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.5%. Embecta’s dividend payout ratio is 41.96%.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.